JP2009511000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511000A5 JP2009511000A5 JP2008530608A JP2008530608A JP2009511000A5 JP 2009511000 A5 JP2009511000 A5 JP 2009511000A5 JP 2008530608 A JP2008530608 A JP 2008530608A JP 2008530608 A JP2008530608 A JP 2008530608A JP 2009511000 A5 JP2009511000 A5 JP 2009511000A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- parent
- seq
- mutation
- variant according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 36
- 230000035772 mutation Effects 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101150030083 PE38 gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71686205P | 2005-09-14 | 2005-09-14 | |
| PCT/GB2006/003384 WO2007031741A1 (en) | 2005-09-14 | 2006-09-12 | Pseudomonas exotoxin a cd4+ t-cell epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511000A JP2009511000A (ja) | 2009-03-19 |
| JP2009511000A5 true JP2009511000A5 (enExample) | 2009-11-05 |
Family
ID=37499328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530608A Pending JP2009511000A (ja) | 2005-09-14 | 2006-09-12 | シュードモナス外毒素ａｃｄ４＋ｔ細胞エピトープ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080193976A1 (enExample) |
| EP (1) | EP1922330A1 (enExample) |
| JP (1) | JP2009511000A (enExample) |
| AU (1) | AU2006290475A1 (enExample) |
| CA (1) | CA2622525A1 (enExample) |
| WO (1) | WO2007031741A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140033391A (ko) * | 2011-06-09 | 2014-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| HK1198170A1 (en) | 2011-09-16 | 2015-03-13 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| US9725512B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | HER3 antibodies binding to the beta-hairpin of HER3 |
| WO2014165282A1 (en) | 2013-03-12 | 2014-10-09 | Institute of Arthritis Research, LLC | Immunologically active polypeptide |
| CN105849120A (zh) * | 2013-10-06 | 2016-08-10 | 美国卫生和人力服务部 | 修饰的假单胞菌外毒素a |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
| WO2018119279A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| WO2019067740A1 (en) | 2017-09-27 | 2019-04-04 | Emory University | FUSION PROTEINS COMPRISING CANCER TOXIN AND MARKER, NANOPARTICLES AND USES THEREOF |
| EP3820903A1 (en) | 2018-07-12 | 2021-05-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Affinity matured cd22-specific monoclonal antibody and uses thereof |
| WO2020033430A1 (en) | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| EP3883608A1 (en) | 2019-01-08 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
| AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| CN114729041B (zh) | 2019-10-22 | 2024-12-31 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体 |
| WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| US20240218055A1 (en) | 2021-04-29 | 2024-07-04 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| US20240270851A1 (en) | 2021-06-09 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
| WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024104584A1 (en) | 2022-11-17 | 2024-05-23 | University Of Cape Town | Deimmunized pseudomonas exotoxin a |
| WO2024238346A1 (en) | 2023-05-12 | 2024-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof |
| WO2025019228A1 (en) | 2023-07-20 | 2025-01-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors |
| WO2025171238A1 (en) | 2024-02-07 | 2025-08-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5458878A (en) * | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| ES2342929T3 (es) * | 2001-09-26 | 2010-07-19 | The Government of the United States of America as represented by the Secretary of Health and Human | Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22. |
| AU2004293471C1 (en) * | 2003-11-25 | 2011-02-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-CD22 antibodies and immunoconjugates |
-
2006
- 2006-09-12 CA CA002622525A patent/CA2622525A1/en not_active Abandoned
- 2006-09-12 AU AU2006290475A patent/AU2006290475A1/en not_active Abandoned
- 2006-09-12 US US12/066,709 patent/US20080193976A1/en not_active Abandoned
- 2006-09-12 JP JP2008530608A patent/JP2009511000A/ja active Pending
- 2006-09-12 EP EP06779398A patent/EP1922330A1/en not_active Withdrawn
- 2006-09-12 WO PCT/GB2006/003384 patent/WO2007031741A1/en not_active Ceased
-
2010
- 2010-08-02 US US12/848,387 patent/US20100291150A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511000A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| ES2916101T3 (es) | Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad | |
| JP2007197439A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| JP2011526480A5 (enExample) | ||
| RU2013153816A (ru) | Варианты альбумина | |
| WO2009051555A3 (en) | Modified mhc class i binding peptides | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| JP2015523328A5 (enExample) | ||
| WO2005086794A3 (en) | Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor | |
| JP2012152218A5 (enExample) | ||
| JP2005512574A5 (enExample) | ||
| RU2013148919A (ru) | Рекомбинантный иммунотоксин, нацеленный на мезотелин | |
| JP2009527226A5 (enExample) | ||
| MY149128A (en) | A method for the mass production of immunoglobulin fc region deleted initial methionine residues | |
| WO2008138649A3 (en) | Signaling peptides | |
| ES2582802T3 (es) | Uso de lisozima como marcador | |
| PE20020857A1 (es) | Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras | |
| MX2009003188A (es) | Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos. | |
| Osaki et al. | Development of a bispecific antibody tetramerized through hetero‐associating peptides | |
| CN107267537B (zh) | 一种杂合抗菌肽mlh的制备方法 | |
| JP2016512251A5 (enExample) | ||
| MX2010010025A (es) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. | |
| CN105838694A (zh) | 一种融合标签蛋白 |